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Abstract  
Background  
Pelvic organ prolapse (or prolapse) is a common condition in women where the pelvic 
organs (bladder, bowel or womb) descend into the vagina and cause distressing symptoms 
that adversely affect quality of life. Many women will use a vaginal pessary to treat their 
prolapse symptoms.  Clinic based care usually consists of having a pessary fitted in a primary 
or secondary care setting, and returning approximately every six months for healthcare 
professional review and pessary change. However, it is possible that women could remove, 
clean and re‐insert their pessary themselves; this is called self‐management. This trial aims 
to assess if self‐management of a vaginal pessary is associated with better quality of life for 
women with prolapse when compared to clinic based care. 
 
Methods 
This is a multicentre randomised controlled trial in at least 17 UK centres. The intervention 
group will receive pessary self-management teaching, a self-management information 
leaflet, a follow up phone call and access to a local telephone number for clinical support. 
The control group will receive the clinic based pessary care which is standard at their centre. 
Demographic and medical history data will be collected from both groups at baseline. The 
primary outcome is condition‐specific quality of life at 18 months’ post-randomisation. 
Several secondary outcomes will also be assessed using participant-completed 
questionnaires. Questionnaires will be administered at baseline, 6, 12 and 18 months’ post-
randomisation.  An economic evaluation will be carried out alongside the trial to evaluate 
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cost-effectiveness. A process evaluation will run parallel to the trial, the protocol for which 
is reported in a companion paper. 
Discussion  
The results of the trial will provide robust evidence of the effectiveness of pessary self-
management compared to clinic based care in terms of improving women's quality of life, 
and of its cost-effectiveness.  
Trial registration 
ISRCTN Registry; ISRCTN62510577, registered on 06/10/2017  
 
Keywords: Prolapse, Pessary, Self-management, Quality of life, Economic Evaluation, 
Randomised controlled trial (RCT),  
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Background and rationale {6a} 
Pelvic organ prolapse affects about 40% of women over 40 years of age [1] and the number 
of women affected is expected to rise [2]. Prolapse is categorised into different stages and 
types and affects women of varying ages. The distressing symptoms include a sensation of 
“something coming down” in the vagina, bladder, bowel and sexual problems and pelvic and 
back pain. These symptoms impact negatively on a woman’s quality of life [3].  
 
Women presenting with prolapse are commonly offered conservative management (such as 
a vaginal pessary or pelvic floor muscle training) or surgery. There were over 28,000 hospital 
admissions in England in 2017/2018 related to female genital prolapse associated with 
approximately 42,000 bed days [4]. About 9.5% of women will undergo surgery for prolapse 
in their lifetime [5].  However, surgery is not always effective or durable with 30% of women 
requiring at least one further procedure [6]. With the high re‐operation rates and the 
controversy surrounding surgery and the use of mesh implants, it is timely to consider the 
evidence supporting conservative options in more detail. 
 
Currently women who have prolapse of all types and stages can receive pessary treatment. 
Most commonly women who use a pessary are over 60 years of age [7] and two thirds of 
women will opt to try a pessary when offered [8]. Although previous research indicates that 
the ring pessary is most commonly used in practice, a wide range of pessaries are fitted [9]. 
Hospital-based care remains the most common delivery mode for women who have a 
pessary with some community‐based clinics and general practices also offering services. The 
most common service model for women is to return to a healthcare professional clinic to 
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have their pessary removed and changed [7]. Most commonly, women attend a clinic 
appointment every six months for a pessary change, but time between changes does vary 
(3‐12 months) [7]. It is not clear if pessaries would be used more often if pessary care was 
less reliant on follow‐up appointments, allowing easier integration of pessary management 
with a woman’s lifestyle. 
 
The largest UK‐based observational study of pessary use reported that 86% of women 
successfully retaining a pessary at four weeks will continue to use a pessary at five years 
[10]. However other studies have reported much lower continuation rates [11–12]. Reasons 
for discontinuation of pessary use include developing complications such as bleeding or 
infection, dislike of the pessary changing procedure and inconvenience of attending 
appointments [13]. 
 
A UK multi‐professional survey found that only 17% of clinicians offered women the option 
of self‐managing their pessary [7]. This is a significant difference in practice compared with 
North America, where the majority of clinicians teach women pessary self‐care [14]. The 
ongoing Cochrane review update has so far identified no completed trials including self‐
management for pessary in any comparison. Self‐management focusses on actions that 
people undertake for themselves to manage their health and illness. In order to self‐manage 
people need self‐management support (actions taken to support people to self‐manage e.g. 
by healthcare professionals). Self‐management has been shown to be effective in improving 
health outcomes such as quality of life in other conditions; e.g. condition‐specific quality of 
life is improved for people with Chronic Obstructive Pulmonary Disease [15]. 
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There is only one small (n=88) non‐randomised study that assesses self‐management of 
vaginal pessaries [16].  Gains from self-management were reported in this study in that 
women reported higher levels of convenience, ability to access help, support and comfort 
than those having clinic management [16]. Women who were self‐managing had one clinic 
appointment scheduled at two years, compared to health care professional clinic based care 
where women attend a clinic every four to six months for pessary changes. Whilst these 
may be promising findings there is an urgent need to robustly investigate whether pessary 
self‐management is more clinically and cost-effective than standard pessary care. The TOPSY 
study aims to address this uncertainty to inform clinical practice.  
 
Objectives {7} 
The aim of the TOPSY trial is to determine the clinical and cost‐effectiveness of self‐
management of vaginal pessaries to treat pelvic organ prolapse, compared to clinic pessary 
care on condition‐specific quality of life. 
 
Methods 
Trial design {8} 
The TOPSY study includes a multicentre, parallel group, superiority randomised controlled 
trial (RCT), an internal pilot study and a nested process evaluation. The RCT and internal 
pilot will be described in further detail here, whilst the protocol for the process evaluation 
will be reported in a separate companion paper and will not be addressed further here.  
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The aim of the internal pilot is to ensure that the TOPSY trial can recruit, randomise and 
retain sufficient numbers of participants while delivering the intervention as planned.  The 
internal pilot will aim to recruit 63 women across six centres (identified prior to the 
commencement of the study). The primary stop‐go rules are detailed in the analysis section.  
 
We will establish if pessary self-management is cost-effective compared to standard clinic 
based pessary care by collecting cost and resource-use data for all participants using a 
combination of NHS data and participant‐completed questionnaires.  This is described in 
more detail in both the outcome section and the analysis sections. 
 
Study setting {9} 
Healthcare providers with pessary care services (who have granted permission for the study 
to take place) will identify and recruit women (for more information on centres involved 
please see https://w3.abdn.ac.uk/hsru/TOPSY/Public/Public/index.cshtml).   
 
Eligibility criteria {10} 
Women will be eligible for inclusion if they are aged 18 or older, use a pessary of any 
type/material (except those that require more complex removal techniques such as Shelf or 
Gellhorn pessaries and those that must be self-managed such as cube pessary) and have 
retained the pessary for at least two weeks. Women will be ineligible if they: have limited 
manual dexterity that would affect their ability to remove and replace their own pessary; 
are judged by their healthcare team to have a cognitive deficit such that it is not possible to 
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obtain informed consent or to self-manage; or are pregnant. The self-management teaching 
is only available in English therefore sufficient understanding of English language is required 
for participation. 
 
Recruitment {15} 
Potential participants will be identified in the following ways: 
1. Reviewing patient notes, clinic lists or caseloads to identify women who are 
currently using a pessary and could be approached; 
2. At a pessary appointment when women attend for pessary review (existing users) 
or are fitted with a pessary for the first time (new users); and 
3. Women who learn about the TOPSY study themselves (website, posters, word of 
mouth) and approach their centre or the trial office (this would be dependent on 
there being a TOPSY recruitment centre local to the women). 
 
Women who are identified as potential participants through the mechanisms detailed above 
will be given a recruitment pack which contains an introductory letter, a participant 
information leaflet, an expression of interest form and a reply paid envelope. Women 
identified via patient notes, clinic lists or caseloads will have the recruitment pack posted to 
them by the “local TOPSY clinical team”. Women identified at their pessary appointment will 
be given the same recruitment pack in clinic. If time restraints in clinic mean that the local 
TOPSY clinical team are unable to fully discuss the study with the woman after giving out a 
pack, a follow-up call with the woman from a member of the research team at the centre 
delegated to do so can be arranged for an agreed time. 
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Once women have had enough time to make their decision, they can return the expression 
of interest form by post or in person to the local TOPSY clinical team to indicate if they are 
interested in participating or not. On receiving a positive expression of interest form, a 
member of the local TOPSY clinical team will discuss the study further with the woman and 
screen her for eligibility. 
 
In addition, for women who are new pessary users (used a pessary for 3 months or less), 
eligibility screening will be finalised by a telephone call to assess if the pessary has been 
retained for at least two weeks. If the pessary has not been retained for two weeks, 
standard centre protocol would be followed for further pessary care. If women indicate that 
they remain interested in participating in TOPSY, eligibility will be reassessed once standard 
centre protocol is followed and the pessary has been retained for two weeks. 
 
Who will take informed consent? {26a} 
If a woman is eligible and willing to take part, she will be asked to come to a baseline clinic 
appointment to provide written, informed consent for randomisation and completion of 
baseline questionnaires and demographic data (see outcome section for more information).  
 
Informed consent procedures will ensure that women understand participation is voluntary 
and that participants can withdraw from all or any part of the research at any time without 
affecting their participation in other parts of the study, or their healthcare. Women may 
choose to withdraw from the treatment aspect of the study, but continue to provide data, 
for example by completing questionnaires. Where women cannot, or choose not to, 
continue to self‐manage this will be recorded and women, where willing to do so, will 
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continue to complete questionnaires. If withdrawal occurs, the primary reason for 
withdrawal will be documented in the participant’s Case Report Form (CRF), if possible. 
After full withdrawal, no further data will be collected from the participant but data 
collected up to that point will be analysed. 
 
If a participant is randomised and then withdraws prior to any trial intervention being 
undertaken, for trial purposes the woman will continue to be included within her original 
allocated group, and if data are available, in the intention to treat (ITT) analysis. If women in 
the self-management group cross over to clinic based care during the trial they will follow 
the trial clinic based care group protocol. A change of status form will be completed in all of 
the above examples to indicate the nature of the change of status and to monitor 
participant attrition rates. The Data Monitoring and Ethics Committee (DMEC) will review 
change of status information at an appropriately agreed frequency.  
 
Additional consent provisions for collection and use of participant data and biological 
specimens {26b} 
The main trial consent asks participants if they would be willing to be contacted about the 
interviews (for the process evaluation part of TOPSY) or if they would be willing to have 
their teaching session or their two-week follow up call audio-recorded.  They are also asked 
if they would be happy to be contacted in the future about research.  Participants can say 
no to any of these questions and still take part in the TOPSY study. 
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Assignment of interventions 
The trial is supported by The Centre for Healthcare Randomised Trials (CHaRT; a fully 
registered UK CRN clinical trials unit in the Health Services Research Unit, University of 
Aberdeen). CHaRT will develop the data management system, a remote randomisation 
system, and will be responsible for ensuring the reliability of data at data‐lock and 
compliance with the Research Governance Framework and Good Clinical Practice. 
 
Sequence generation {16a} 
Randomisation will be minimised (naïve minimisation) by age (<65/≥65 years), pessary user 
type (new user/ existing user) and centre.  
 
Concealment mechanism {16b} 
This randomisation application will be available as an internet based service, located within 
the TOPSY data management system.   
 
Implementation {16c} 
A trained and delegated member of the local TOPSY research team will randomise women 
at each centre by accessing the data management system and entering the required 
information, which will generate the group allocation and display it on screen/and relay this 
information in an email. 
 
Who will be blinded? {17a} 
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The trial group to which women are allocated cannot be masked from the participants or 
the centre staff after randomisation has occurred. Blinding is therefore not possible. 
 
Procedure for unblinding if needed {17b} 
Unblinding is not applicable. 
 
Intervention description {11a} 
Self‐management interventions are highly heterogeneous [14; 16-18], making identification 
of the effective component parts of an intervention difficult. However, based on evidence 
drawn from large scale self‐management programmes, three tasks need to be achieved in 
order for individuals to self‐manage [17]: medical management of the condition; role 
management and emotional management.  
 
Pessary self‐management 
To support a woman to achieve the three tasks needed for self‐management the 
intervention will be directed at three levels: 
• at service level to facilitate a supportive culture for a self‐management treatment 
pathway. 
• at professional level to ensure that staff have the self‐management teaching and 
support skills. 
• at individual woman level to ensure women can achieve the necessary tasks to self‐
manage. 
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Supporting delivery of self‐management at service and professional levels 
At service level, the TOPSY training team (a clinical co‐applicant and the trial manager) will 
visit all trial centres and will discuss with staff the trial processes and the self‐management 
protocol.  
 
A training manual for those staff teaching women self‐management has been developed: 
with Patient and Public Involvement (PPI) input (including a focus group with women from 
the Royal College of Obstetricians and Gynaecologists (RCOG) PPI group, Women’s Voices); 
through discussion with our clinical co-applicants (which includes urogynaecologists from 
across the UK, nurses and a physiotherapist); using International Consultation on 
Incontinence recommendations [19]; using best practice guidance from the self‐
management literature.  
 
Intervention components delivered to individual women 
Women allocated to self-management will receive: a self-management teaching 
appointment, a self-management information leaflet, a two week follow up telephone call, 
and a telephone helpline number/ email address for their local clinical site. 
 
Each woman in the self‐management group will receive a 30 minute, one‐to‐one self‐
management teaching appointment with an intervention healthcare professional (HCP) 
who has been trained in the pessary self‐management intervention by the TOPSY training 
team. The intervention HCP is most likely to be a specialist nurse or physiotherapist, but 
may also be a urogynaecologist or General Practitioner (GP).  They have to be involved in 
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pessary management as part of their clinical role to be eligible to teach women the 
intervention for the TOPSY study. The teaching appointment should take place within 4 
weeks of the randomisation date. The self-management training manual specifies in detail 
the key components of the self‐management intervention, facilitating standardisation of the 
self‐management intervention across the centres. The key components as laid out in the 
training manual will be used by the intervention HCP when teaching women within the 
teaching appointment. 
 
During the self‐management teaching appointment, women will be given a self‐
management information leaflet containing written information on pessary self‐
management. The leaflet was initially developed as part of a previous non‐randomised study 
[16] and is based on the viewpoints of, and feedback from, PPI representatives. The leaflet 
has undergone further development, drawing on the expertise of TOPSY PPI 
representatives, Women’s Voices (RCOG) focus group members and clinical co‐applicants. 
The leaflet includes diagrams of various pessary types and pelvic floor anatomy, information 
about common complications and what to do if these are experienced. The same leaflet will 
be used across all centres.  
 
Strategies to improve adherence to interventions {11c} 
During the self-management teaching session and reinforced in the self-management 
leaflet, women in the self‐management group will be asked to remove, clean and re‐insert 
their pessary at least once in the two weeks following the self‐management teaching 
appointment. The woman will be telephoned two weeks after the appointment and asked 
if she has been successful in removing, cleaning and re‐inserting her pessary. They will 
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discuss any difficulties experienced. If the woman has not changed the pessary, the HCP will 
ask her to do so over the next week, and will call her again to check if this has been 
achieved. Where a woman has experienced difficulty that requires assessment by the HCP 
or where the woman has not changed the pessary by the time of the second phone call, she 
will be offered a second self‐management teaching appointment. If, after this second 
appointment, the woman is unable to self‐manage or does not wish to do so, she will be 
given the choice to transfer to clinic based pessary care. All information on these 
interactions with women and any subsequent crossovers will be recorded in the study 
specific CRF. Once it is clear that the woman has been able to remove and re‐insert the 
pessary at least once, she will be asked to remove and re‐insert the pessary at least once 
every six months. This information will be given as part of the self‐management teaching 
appointment and is written into the information leaflet. 
 
Women in the self‐management group will receive a local telephone number and an email 
address to use to make contact with the intervention HCP at their centre if they experience 
any pessary problems or have questions (numbers of contacts received and details of 
reasons for calls will be recorded by the centre).  
 
Women with PVC pessaries in both groups will receive a new PVC pessary every six months 
(women in the self‐management group will either receive their new pessary by post or by 
picking up a prescription or some centres may give 2 extra pessaries at the baseline visit).  
 
Women in the self‐management group with silicone pessaries, which are more durable, will 
only have the pessary changed by request if required (e.g. if the pessary becomes damaged) 
 TOPSY Protocol Paper Final V2 (amended for editors comments) for submission 19-02-20 
  Page 19 of 44 
 
and women with silicone pessaries in the clinic based care group will have the pessaries 
changed as per local centre protocol. Self‐management leaflets will include information 
about what women need to do if they require a new pessary. 
 
Women in both trial groups will be asked to complete questionnaires every six months 
which will include questions regarding their patterns of pessary removal and re‐insertion. At 
18 months after randomisation women in both groups will attend a clinic appointment 
which will include an examination of vaginal tissues, comparable to that carried out 
routinely in clinic based pessary care (see below). 
 
Provisions for post-trial care {30} 
Care will continue as normal for women in the standard care group.  Local centres can 
provide training on self-management if this service is currently offered.  For women who 
have been in the self-management group it will be up to them and each local centre how 
often women are seen back in clinic.  We will capture this information in the end of study 
Case Report Form. 
 
Criteria for discontinuing or modifying allocated interventions {11b} 
There are no special criteria for discontinuing or modifying allocated interventions.  
Participants may choose to revert back to standard care themselves for any reason or may 
choose to stop using a pessary. 
 
Relevant concomitant care permitted or prohibited during the trial {11d} 
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No special provisions 
 
Explanation for the choice of comparators {6b}- Clinic based pessary care 
Women will receive a clinic appointment for their pessary care according to the local 
management pathway. Content of appointments will follow local protocol which usually 
includes vaginal examination to remove the pessary, inspection of the vaginal tissues and 
insertion of a new pessary. Data on frequency of appointments and of pessary changes at 
appointments will be recorded in the CRF. Healthcare professionals who deliver standard 
pessary care at each centre will be interviewed as part of the process evaluation allowing 
variation in standard pessary care to be described. 
 
Recruitment and retention of study centres 
Each collaborating centre will appoint a local Intervention HCP as part of the local TOPSY 
research team who will be trained on the self‐management intervention and who will keep 
regular contact with the local PI, with notification of any problems or unexpected 
developments. Each centre will have a centre initiation visit to ensure all study processes 
are in place before recruitment commences. The TOPSY Study Office will set up regular 
centre ‘forums’ for all centres to ‘phone in’ and discuss any problems experienced and share 
learning. Updates will be provided via quarterly newsletters. Centres having specific 
problems with recruitment and/or retention will be offered additional support either 
remotely or by an additional centre visit. 
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Outcomes {12} 
Plans for assessment and collection of outcomes {18a} 
Throughout the TOPSY study, data will be gathered from the women in the trial, and the 
TOPSY clinical research staff at each study centre.  The outcome measures collected are 
described in the sections below and in Table 1 
[Table 1 to be inserted here] 
Primary outcome 
The primary outcome, condition‐specific quality of life at 18 months post‐randomisation, 
will be measured via participant‐completed questionnaires using the PFIQ‐7. The PFIQ‐7 [20] 
is a reliable, valid and responsive short‐form of the Pelvic Floor Impact Questionnaire (PFIQ) 
which measures condition‐specific quality of life in women with pelvic floor disorders 
including urinary incontinence, prolapse and faecal incontinence.  There are three subscales:  
Urinary (UIQ-7), Colorectal-anal (CRAIQ-7) and Pelvic organ prolapse (POPIQ-7), with each 
sub-score ranging from 0-100 and a total score ranging from 0-300. Data will be collected at 
each time‐point to allow repeated measures analysis of the PFIQ‐7 scores.   
 
Secondary outcome measures 
Several secondary outcomes will be collected as described below. Frequency of collection 
for each outcome is shown in table 1. 
 
Participants’ health related quality of life, will be measured by Euroqol (EQ‐5D‐5L) 
complementing the primary outcome measure of condition‐specific quality of life, and also 
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providing data for the analysis of cost‐effectiveness (see section on data collection for 
economic evaluation for more information).  
 
The severity of prolapse‐related symptoms will be measured by PFDI‐20. This was developed 
and validated in parallel with the PFIQ‐7 [20]. It contains 20 questions about the presence of 
bladder, bowel and pelvic symptoms, and how bothersome these are.  
 
Women’s sexual symptoms will be assessed by The Pelvic Organ Prolapse/Urinary 
Incontinence Sexual Questionnaire (PISQ‐IR) [21]. 
 
A woman’s general self‐efficacy (as a moderator of quality of life) will be measured by the 
General Self Efficacy scale (GSE) [22] 
 
Pessary Complications  
A new pessary questionnaire developed for TOPSY (with 15 possible complications of 
pessary use), developed based on the literature, PPI opinion, and the team’s experiences in 
the pilot study, will be used to record women’s pessary complications (e.g. discharge, odour, 
pain, discomfort, bleeding). The questionnaire record will be used to collect the secondary 
outcome measure of pessary related complications to report on the   impact and safety of 
the trial interventions. 
 
Pessary Use  
A new questionnaire (including eight questions) developed based on the literature, PPI 
consultation, and the team’s experiences in the pilot study, will be used to collect data on 
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the pattern of a woman’s pessary use, including pessary continuation and perceived 
acceptability and benefit. This will include questions that ask women: whether or not they 
are still using a pessary as treatment for prolapse; when they last removed and re‐inserted 
their pessary; reasons for pessary removal; interference of the pessary with everyday life; 
and if they find the pessary an acceptable treatment. Also included is a question adapted 
from the Patient Global Impression of Improvement (PGI‐I) which will be used to assess 
perceived benefit of the pessary care regimens being evaluated. The PGI‐I is a single‐item 
tool asking the individual to rate the change in their condition since having treatment, which 
has been validated for urogenital prolapse [23-24]. An amended version asking women to 
describe how they feel about their pessary care since taking part in the study will be used, 
with response options ranging from very much better to very much worse. Patterns of 
pessary use are used to measure impact, adherence, and acceptability of the trial 
interventions. 
 
Pessary Confidence (to measure pessary specific self‐efficacy) 
No suitable condition‐specific measure exists, thus questions relating to pessary self‐efficacy 
were developed based on the guidance from Bandura [25]. These six questions have been 
developed with PPI representatives, PPI input, statistical input and clinical team members. 
We will use both the generic validated measure of self‐efficacy (GSE) and the responses to 
the newly developed pessary‐specific self‐efficacy questions to measure self‐efficacy and 
help us understand the influence it has as a moderating factor on quality of life. 
 
Uptake of additional treatment for prolapse 
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As an indicator of intervention effectiveness, the uptake of other treatment for prolapse 
since the start of the study, or treatment awaited, will be recorded in participant 
questionnaires (e.g. surgery, pelvic floor muscle training, oestrogen, lifestyle advice). 
Women’s access to professional pessary related support since starting the study will also be 
recorded (e.g. telephone support, hospital appointment, GP appointment). These data will 
be collected at all trial time‐points to improve data quality as they rely on women recalling 
events occurring over a period of some months. Additional treatment will be described as 
part of the main trial findings to assist in understanding adherence and level of support 
women need, as well as being used as part of the cost-effectiveness analysis. 
 
Uptake of telephone support related to pessary use 
Using a Telephone Support Log Form we will ask the intervention HCP who receives 
women’s calls to record frequency and details of all calls received to the telephone support 
line. There will be a question in the pessary complication questionnaire that asks ALL 
women if they required telephone support as some women in the clinic based care group 
may also telephone for support from their local team. This will help understanding of 
adherence, effectiveness and level of support relating to the trial interventions. 
 
Adherence to randomised protocol 
Adherence to the self‐management or clinic based care protocol will be monitored 
throughout the trial. Monitoring will be via multiple data sources: questions within the 
pessary use questionnaire; telephone support contacts; and health records. It will include 
crossover to the other trial group (i.e. self‐managing women opting to move to clinic based 
care). Clinic based care women will not have access to the trial self‐management teaching 
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and support intervention, but they may choose to remove and replace their pessary at 
home and this will be recorded in the pessary use questionnaire.  
 
Health of vaginal tissues: At baseline and 18 months, women will have a vaginal 
examination undertaken at the clinic by a healthcare professional to assess the health of the 
vaginal tissues and identify problems associated with pessary use, for example, tissue 
granulation or ulceration. Any findings will be recorded in the CRFs. 
 
Biological Specimens {33} 
No biological specimens are collected as part of TOPSY. 
 
Data collection for Economic Evaluation 
An economic evaluation will be conducted alongside the main trial. For both groups, the EQ‐
5D‐5L will be completed as part of the participant questionnaires at baseline, 6, 12 and 18 
months (http://www.euroqol.org/) to allow estimation of QALYs for a cost-utility analysis. In 
both trial arms resource use will be captured by a combination of health data and 
participant‐completed questionnaires. Questionnaires will be completed at 6, 12 and 18 
months.  Resource use related to appointments will be captured from patient case record 
forms at each appointment.    
 
Overall costs will be estimated by multiplying resource use by unit costs obtained from the 
appropriate sources including trial specific costs, NHS reference costs, Unit costs of Health 
and Social Care and the British National Formulary (BNF). 
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Plans to promote participant retention and complete follow up {18b} 
Active measures to minimise loss to follow-up of women include: 
1. Recording at the outset women’s email addresses and mobile phone numbers, their 
preferred method of contact (for follow up contact) and their preferred method of 
completion of questionnaires.  Questionnaires can be completed online (via an email link) or 
in paper format and returned by post. 
2. Participants who do not return their questionnaires within three weeks will be sent up to 
three reminders using a variety of methods (post/email/ text message dependent on 
participants preferred method). The third reminder will be by telephone where the 
researchers will aim to gather, at a minimum, the primary outcome data during the call.  
3. Response rates to the self-reported questionnaires will be monitored to ensure they 
remain above 80% (the level assumed in the sample size calculation).  If response rates are 
seen to drop, the team will discuss appropriate actions with the Project Management 
Group.  Relevant action may include phone calls at different times of day or asking women 
to only complete the primary outcome measure.  
 
Data Management {19} 
All participants are given an individual study ID which will be used on all Case Report Forms 
for that participant. Data will be entered into the secure database by the data coordinator 
based at the TOPSY study office at Glasgow Caledonian University.  Local Centre staff will 
only enter the information required for randomisation (consent and eligibility information). 
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Sample size {14} 
The aim is to recruit a sample size sufficient to detect a 20‐point difference in the PFIQ−7 
score, which we consider to represent an important clinical difference (the potential range 
of the PFIQ‐7 is 0 to 300). A sample size of 330 women (165 per group) is required to 
provide 90% power to detect a difference of 20 points in the PFIQ−7 score at 18 months, 
assuming a standard deviation of 50 based on previous studies [26-27], two‐sided alpha of 
0.05, and 20% loss to follow‐up. In order to detect this standardised effect size of 0.4 SDs 
(20/50 points), 132 women will need to be recruited per group, or 165 per group to allow 
for dropout.  
 
Stopping guidelines {21b} 
Data from the internal pilot will be examined and the following stop-go rules will apply [28-
29]  
• If the overall recruitment rate across pilot centres is 75% or more of the total 
expected recruitment (i.e. at least 47 out of 63) the trial will continue. 
• If the recruitment rate is 50‐75% (31‐46 women), the trial will continue with a clear 
plan to overcome barriers to recruitment that is based on review of screening logs at 
centres, the trial protocol and the qualitative recruitment data (process evaluation). 
• If the recruitment rate is 25‐50% (16‐30 women), screening logs, the protocol and 
the qualitative recruitment data (process evaluation) will be reviewed and the trial 
will only continue after discussion with and approval by NIHR HTA and with a clear 
plan to recruit within more centres and address the recruitment shortfall. 
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• Should recruitment be <25% (15 women or less), we will enter into discussions with 
the funder but it is not expected the trial will progress. The decision to stop the trial 
will be made by the TSC and the funder. 
 
In addition, we have set the following secondary targets: 
• 40% of eligible new and 20% of eligible existing pessary users invited agree to 
randomisation; 
• 60% of the pilot self‐management women (n=19 of 31 women randomised to self-
management) still self‐managing at two-week telephone follow‐up (i.e. have 
removed and re‐inserted their pessary at least once). 
 
Statistical methods for primary and secondary outcomes {20a} 
A single main analysis will be performed at the end of the trial when 18‐month follow‐up 
has been completed. The independent DMEC will review confidential interim analyses of 
accumulating data at its discretion but at least annually. All analyses will be conducted 
according to a pre‐specified statistical analysis plan. 
 
All outcomes will be described with the appropriate descriptive statistics: mean and SD for 
continuous outcomes (or medians and interquartile range for skewed data), and counts and 
percentages for dichotomous and categorical outcomes. 
 
The main effectiveness analysis will be based on the ITT principle. The analysis of the 
primary outcome will estimate the mean difference (with 95% confidence intervals) in the 
PFIQ−7 score at 18 months between the self‐management and standard care groups using a 
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mixed effects repeated measures model (which assumes incomplete outcome data to be 
missing at random). The model will incorporate age (<65/ ≥65) and pessary user type 
(new/existing) and baseline PFIQ-7 as fixed effects and participant and recruitment centre 
as random effects. Statistical significance will be at the 5% level. 
 
Secondary outcomes will be analysed using an appropriate generalised linear model, for 
example binary logistic regression for dichotomous outcomes such as discontinuation with 
pessary (Y/N), and ordinal logistic regression for ordered categorical outcomes such as 
women’s global impression of improvement (PGI‐I). All models will be adjusted for 
minimisation covariates (age, pessary user type and centre) and baseline score (where 
applicable). 
 
Methods in analysis to handle protocol non-adherence and any statistical methods to 
handle missing data {20c} 
The missing at random assumption for primary outcome data will be assessed further in 
sensitivity analyses. Treatment effects will be estimated under varying assumptions of data 
being missing not at random using pattern‐mixture models. A complete case analysis will 
also be conducted. 
 
Given the potential for crossover, we will conduct a secondary analysis of compliers to 
estimate the effect of receiving the self‐management intervention, using complier average 
causal effect (CACE) estimators. The CACE analysis will take a maximum likelihood approach, 
which can assume incomplete data to be missing at random, and can be adjusted for 
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covariates. This analysis will provide unbiased effect estimates of receiving the self‐
management intervention, which will complement the ITT effect estimates. 
 
Methods for additional analyses {20b} 
Subgroup analyses will be carried out within the following groups: age (<65/≥65 years) 
hysterectomy (Y/N) and type of pessary user (new versus existing). Stricter levels of 
statistical significance (2P<0.01) will be sought, reflecting the exploratory nature of these 
analyses. Heterogeneity of treatment effects amongst subgroups will be tested for using the 
appropriate subgroup by treatment group interactions [30].  
 
Economic Analysis 
Cost‐Effectiveness Analysis 
The primary analysis will be undertaken at 18 months from an NHS perspective. All costs 
and outcomes beyond one year will be discounted at 3.5% [31]. A broader perspective 
including women’s personal expenditures will be included in a sensitivity analysis. 
Incremental cost effectiveness ratios (ICERs) will be computed by comparing the costs and 
outcomes of the self-management and clinic based care trial groups. The difference in 
effectiveness will be expressed in terms of the change in score on the primary outcome 
measure PFIQ‐7 (cost‐effectiveness analysis). The difference in utility between the two 
groups will be expressed in terms of QALYs calculated using the UK value set for patient‐
reported EQ‐5D‐5L data [32]. This will be used in a cost-utility analysis to calculate the 
incremental cost per QALY gained. 
 
Longer term Decision Modelling 
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To examine the costs and outcomes of self‐management compared to clinic based care 
beyond the trial period, a decision analytic model will be developed. This will involve 
extrapolating data from the trial period and supplementing with additional data from the 
literature and other data sources as required. A five‐year time frame will be used and the 
care pathway over this period will be mapped out. We will incorporate data on: number of 
women who would want to self‐manage, continued pessary use, continuation rates for self‐
management, complications and adverse events, conversion to surgery rates for both self‐
management and clinic based care, health outcomes (prolapse and general quality of life 
outcomes), expenditure attending follow‐up appointments in both groups, expenditure on 
replacement pessaries in both groups (type‐dependent), other (potentially rare) outcomes 
of interest that we would unlikely to see during the 18 month trial period (e.g. fistula). Using 
this model we will perform cost-effectiveness analyses by synthesising trial data and data 
from other sources. Robustness of the results will be assessed through probabilistic 
sensitivity analyses. This will allow us to examine longer term outcomes and cost-
effectiveness under the presence of uncertainty.  
 
Interim Analyses {21b} 
A single main analysis will be performed at the end of the trial when 18 month follow up has 
been completed. The DMEC will review confidential interim analysis of accumulation data at 
its discretion but at least annually. 
 
Composition of the coordinating centre and trial steering committee {5d} and composition 
of the data monitoring committee, its role and reporting structure {21a} 
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An independent Trial Steering Committee (TSC) will review the study on behalf of the 
sponsor and the funder. A separate and independent Data Monitoring and Ethics 
Committee (DMEC) will be convened.  Both committees will have an independent chair. The 
DMEC will report to the TSC.  During the period of recruitment to the trial, the DMEC will 
review a report on accumulating safety data at each meeting, together with other analyses 
that the committee may request.  
 
The trial will also be overseen by a Project Management Group (PMG; consisting of the 
grant applicants, the trial staff and 3 public and patient representatives). 
 
Frequency and plans for auditing trial conduct {23} 
The TSC and DMEC will meet every 6 months during recruitment and then annually.  The 
PMG will meet (via teleconference) every 6 to 8 weeks. The TOPSY study office will monitor 
the quality of the data returned by the study centres and action accordingly.  
 
Adverse event reporting and harms {22} 
All women in the TOPSY study have had a vaginal pessary inserted. As a foreign body placed 
in the vagina, this is recognised as a potential cause of specific symptoms e.g. bleeding and 
vaginal ulceration/erosion. Expected events arising from pessary treatment are noted below 
and thus will NOT be collected as adverse events but will be recorded: 
• Granulation of vaginal tissue 
• Involuntary expulsion of pessary 
• Vaginal smell 
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• Vaginal discharge 
• Bleeding during pessary change. 
 
The questionnaires completed at 6, 12 and 18 month follow up include a pessary 
complication questionnaire where women will indicate any complications they have 
experienced.   
 
In the clinic based care group, the local clinical TOPSY research team will ask about the 
occurrence of AEs/SAEs at every pessary follow up appointment. Open‐ended and non‐
leading verbal questioning of the participant will be used to enquire about AE/SAE 
occurrence. Participants will also be asked if they have been admitted to hospital, had any 
accidents, used any new medicines or changed medication regimens. If there is any doubt as 
to whether a clinical observation is an AE, the event should be recorded. Women in the self‐
management group are asked during the teaching appointment and advised in the 
information leaflet to call the telephone helpline if they experience any of the symptoms 
that may be indicative of an SAE/AE. The Pessary complication questionnaire completed by 
all women at all time‐points will also capture any adverse events experienced. 
 
We have adhered to the new structured study protocol template which includes all SPIRIT 
headings and item identifiers. 
 
Dissemination plans {31a} 
In addition to the main funding report, journal publications and conference presentations, 
we will make the training manuals and materials available online and training days will be 
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arranged.  Where possible our relevant patient and clinical representatives will be part of 
the dissemination activities (training days, presentations). 
 
Plans for communicating important protocol amendments to relevant parties (e.g. 
trial participants, ethical committees) {25} 
Funders, sponsors and National Health Service Research & Development Offices will be 
notified routinely and appropriate approvals gained and communicated as required by them 
and by the trial sponsor. 
 
Plans to give access to the full protocol, participant level data and statistical code {31c} 
The full Trial Protocol is available on the funders website 
(https://www.journalslibrary.nihr.ac.uk/programmes/hta/168201/#/). A second paper 
detailing the process evaluation of TOPSY has been submitted to TRIALS as a companion 
paper. Anyone interested in other data or documentation should contact the corresponding 
author. 
Discussion 
Due to the anticipated rise in the prevalence of prolapse with an ageing population, there will 
be an anticipated increasing demand on pessary management services which will have 
increased cost implications across all NHS trusts.   Some pessary management services in 
different regions across the UK offer women the option to learn how to self-manage their 
own pessaries but there is limited evidence to support this practice.  There is currently no 
“gold standard” on how self-management is taught to women, no evidence on the support 
structures that should be available to support self-managing women or on how often 
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women should be seen in clinic if self-managing. The TOPSY study is therefore crucial to 
evaluate the effectiveness of self‐management on a woman’s quality of life and the 
potential impact on current and future NHS workload. TOPSY is the first trial of self-
management in pelvic floor dysfunction. 
 
Previous pessary trials, where women are randomised prior to pessary fitting, have an 
attrition rate of approximately 40% [26; 33-34]. A particular strength of the TOPSY trial 
design is to ensure that women have managed to retain their pessary for at least 2 weeks 
before they are eligible to be randomised.   It is anticipated that having less attrition will 
support a true test of whether or not self-management is more effective in improving 
women’s quality of life than clinic based care. 
 
If the TOPSY study concludes self-management has a positive effect on a women’s quality of 
life in regards to management of pelvic organ prolapse and has cost benefits to the NHS, it is 
hoped that the intervention package (including the training manuals and literature 
developed for TOPSY) will be rolled out and implemented across the UK.  
 
Confidentiality {27} 
All investigators and study centre staff involved in this study will comply with the 
requirements of the General Data Protection Regulations (GDPR) and the Data Protection Act 2018 
in regards to the collection, storage, processing and disclosure of personal information.  
Data collected during the course of the research is kept strictly confidential and accessed only by 
members of the research team and may be looked at by individuals from the Sponsor organisation 
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or NHS sites where it is relevant to the participant taking part in this trial.   
 
Trial Status and Internal Pilot  
The first participant was randomised on the 16th May 2018. All six pilot centres were 
recruiting by June 2018 and 72 participants were recruited by the end of the pilot phase on 
16 November 2018. The principal stop/go criterion was therefore met and the trial 
continued. 
The secondary target of at least 60% of women self-managing at two weeks was also met 
with 83% of those randomised to self-management still self-managing at two weeks. The 
target of 20% of existing users was exceeded with 22% of eligible existing users randomised.  
The target of 40% of new users was not met with only 28% of eligible new users 
randomised.  This lower than anticipated figure led to a re-profiling of recruitment. As a 
consequence, the number of centres was increased, currently 21 centres are open to 
recruitment across the UK, and the recruitment period was extended until January 2020.  
Data collection will continue until 2021. As part of the process evaluation, data was 
gathered about participant recruitment processes, the findings of these elements of the 
pilot study will be submitted for publication imminently. 
 
Declarations 
Ethics approval and consent to participate {24} 
The TOPSY trial received ethical approval from the West of Scotland Research Ethics Service, 
West of Scotland REC 3 (17/WS/0267) on the 17th February 2018 and the NHS Health 
 TOPSY Protocol Paper Final V2 (amended for editors comments) for submission 19-02-20 
  Page 37 of 44 
 
Research Authority on the 9th March 2018.  All participants will give verbal and written 
informed consent. 
 
 
Consent for publication {32} 
Written consent will be obtained from all participants to use anonymised quotes for 
reporting and publication purposes.  
Availability of data and materials {29} 
All data requests should be submitted to the corresponding author for 
consideration.  Access to anonymised data may be granted following review. 
Competing interests {28} 
All authors declare they have no competing interests.  
Funding {4} 
This study is funded by the National Institute for Health Research Evaluation, Trials and 
Studies Coordinating Centre, Health Technology Assessment (NETSCC HTA) Programme (ref 
16/82/01).  
Footnotes 
This project is funded by the National Institute for Health Research (NIHR) Health 
Technology Assessment Programme (16/82/01). The views expressed are those of the 
authors and not necessarily those of the NIHR or the Department of Health and Social Care 
Authors' contributions {31b} 
 TOPSY Protocol Paper Final V2 (amended for editors comments) for submission 19-02-20 
  Page 38 of 44 
 
All named authors adhere to the authorship guidelines of Trials.  All authors have agreed to 
publication.  
CB, RK, SH, AE, SM, MG, WA, LD, RT, DMcC, KGu, MF, CH, MF, JN, HM and SB developed the 
protocol. MG provided PPI feedback on the protocol and components of the intervention 
and study materials. CB, RK, SH, KG, AE, SM, MG, WA, LD, RT, DMcC, KGu, MF, CH, MF, JN, 
HM and SB contributed to study conception and design, and project planning. KG and LM, 
are responsible for the day to day management of the trial and the data. HM and SM are 
responsible for the economic evaluation.  CB, SH, KG, LM and RK prepared the initial 
manuscript. RK and SH share oversight of the trial elements of the study.  
All authors reviewed the final manuscript prior to submission. All authors read and 
approved the final manuscript. 
Acknowledgements 
We thank the local Principal Investigators and their teams at all participating recruitment 
centres, as well as the women who participate in the TOPSY study. 
 
Participant Timeline {13}  
Table 1: Item 13 in the SPIRIT checklist 
 
Enrolmen
t 
Allocation Follow ups Close-out 
TIMEPOINT -t1 0 6 months 12 months 18 months 
Visits  
Baseline 
Clinic visit 
(a) 
(a) 
End of study 
Clinic visit (a) 
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Screening  and eligibility X     
Informed consent   X    
Allocation  X    
Demographics and 
medical history  
 X 
 
  
INTERVENTIONS:  
Self-management       
Clinic based care      
ASSESSMENTS:  
Primary outcome:      
Condition-specific quality 
of life (PFIQ-7) 
 X 
X 
X X 
Secondary outcomes 
(validated): 
  
 
  
 
Generic quality of life (EQ-
5D-5L) 
 X 
 
X X X 
Pelvic floor symptoms 
(PFDI-20) 
 X 
 
X 
X X 
Sexual function (PISQ-IR) 
 X 
 
 
 X 
General Self-Efficacy (GSE)  X   X 
Secondary outcomes (non-
validated): 
  
 
  
Pessary complications  X  X X 
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 (a) All women will complete their 6, 12 and 18 months follow up questionnaires via a paper questionnaire 
booklet or via a link to complete online (participant preference). Only women in the clinic based care group 
will attend a clinic appointment as per the centres standard care. 
questionnaire X 
Pessary use questionnaire 
(to assess pessary use, 
acceptability and benefit) 
 X 
 
X X X 
Pessary confidence 
questionnaire (to measure 
pessary-specific self-
efficacy) 
 X 
 
 
X 
X X 
Health Resource 
Questionnaire (uptake of 
additional prolapse 
treatment/support) 
  
 
 
X 
X X 
Telephone Support log 
(uptake of telephone 
support related to pessary 
use) 
 Ongoing  
Adherence to randomised 
protocol 
 Ongoing 
Health of vaginal tissues 
(Vaginal examination in 
clinic) (b) 
 X 
 
 
 
 X 
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(b)Women in the clinic based care group will have vaginal tissues assessed at each clinic appointment as per 
standard practice. Women in the self‐management group will have their vaginal tissues assessed at baseline 
and 18 month appointments. 
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